Escolha um dos esquemas abaixo.
Esquema B. Se mau controle com fibratos, associar:
I.
Fibrato.
+
II.
Ômega-3.
Escolha um dos esquemas abaixo.
Esquema B. Se mau controle com estatinas, associar:
I.
Estatina.
+
II.
Ezetimiba
(10 mg/comprimido) 10 mg VO de 24/24 horas.
1.
Volanesorsena (285 mg/1,5 mL)
A dose inicial recomendada é de 285 mg em 1,5 mL, via SC, 1x/semana, durante 3 meses. Após 3 meses, a frequência da dose deve ser reduzida para 285 mg a cada 2 semanas.
Autoria principal: Luiza Ruschel Siffert (Clínica Médica, Endocrinologia e Nutrologia).
Vilar L. Endocrinologia Clínica. 8a ed. Rio de Janeiro: Guanabara Koogan; 2025.
Patel SB, Wyne KL, et al. American Association of Clinical Endocrinology Clinical Practice Guideline on Pharmacologic Management of Adults With Dyslipidemia.Endocr Pract. 2025; 31(2):236-262.
Gouni-Berthold I, Schwarz J, Berthold HK. Updates in Drug Treatment of Severe Hypertriglyceridemia. Curr Atheroscler Rep. 2023; 25(10):701-709.
Waylivra: Volanesorsena. Ana Beatriz Maciel da Fonseca. São Paulo: PTC Farmacêutica do Brasil Ltda; 2023. Bula do medicamento.
Malick WA, Do R, Rosenson RS. Severe hypertriglyceridemia: Existing and emerging therapies. Pharmacol Ther. 2023; 251:108544.
Berberich AJ, Hegele RA. A Modern Approach to Dyslipidemia. Endocr Rev. 2022; 43(4):611-653.
Vilar L. Endocrinologia Clínica. 7a ed. Rio de Janeiro: Guanabara Koogan; 2021.
Santos-Baez LS, Ginsberg HN. Hypertriglyceridemia-Causes, Significance, and Approaches to Therapy. Front Endocrinol (Lausanne). 2020; 11:616.
Parhofer KG, Laufs U. The Diagnosis and Treatment of Hypertriglyceridemia. Dtsch Arztebl Int. 2019; 116(49):825-832.
Sociedade Brasileira de Cardiologia. Atualização da Diretriz Brasileira de Dislipidemias e prevenção de aterosclerose. Rio de Janeiro: SBC; 2017.
Catapano AL, Graham I, De Backer G, et al. 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. Eur Heart J. 2016; 37(39):2999-3058.
Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014; 129(25 Suppl 2):S1-S45.
Berglund L, Brunzell JD, Goldberg AC, et al. Evaluation and treatment of hypertriglyceridemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2012; 97(9):2969-2989.
Thompson WG, Gau GT. Hypertriglyceridemia and its pharmacologic treatment among US adults - invited commentary. Arch Intern Med. 2009; 169(6):578-579.
Ginsberg HN. Hypertriglyceridemia: new insights and new approaches to pharmacologic therapy. Am J Cardiol. 2001; 87(10):1174-1180; A4.
Ballantyne CM, Grundy SM, Oberman A, et al. Hyperlipidemia: diagnostic and therapeutic perspectives. J Clin Endocrinol Metab. 2000; 85(6):2089-2112.